0001415889-24-021731.txt : 20240820
0001415889-24-021731.hdr.sgml : 20240820
20240820184623
ACCESSION NUMBER: 0001415889-24-021731
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240816
FILED AS OF DATE: 20240820
DATE AS OF CHANGE: 20240820
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schneyer Mark C.
CENTRAL INDEX KEY: 0001899977
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50768
FILM NUMBER: 241226758
MAIL ADDRESS:
STREET 1: C/O ACADIA PHARMACEUTICALS INC.
STREET 2: 12830 EL CAMINO REAL, SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070494
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 061376651
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 12830 EL CAMINO REAL
STREET 2: SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-558-2871
MAIL ADDRESS:
STREET 1: 12830 EL CAMINO REAL
STREET 2: SUITE 400
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
4
1
form4-08202024_100820.xml
X0508
4
2024-08-16
0001070494
ACADIA PHARMACEUTICALS INC
ACAD
0001899977
Schneyer Mark C.
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
SAN DIEGO
CA
92130
false
true
false
false
EVP, CHIEF FINANCIAL OFFICER
0
Common Stock
2024-08-16
4
A
0
5275
0
A
39839
D
Common Stock
2024-08-16
4
A
0
13629
0
A
53468
D
Common Stock
2024-08-19
4
S
0
9733
15.28
D
43735
D
Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target.
Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target.
The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
/s/ Jennifer J. Rhodes, Attorney-in-Fact
2024-08-20